breast cancer
Conditions
Interventions
single arm:Change the single dose, number of divisions, and duration of treatment for postoperative regional lymph node radiotherapy
Sponsors
Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: Basic requirements for enrolled patients: 1) Voluntarily participate in and sign informed consent in person 2) Age > 18 years old, 2mm 9) The results of ER, PR, HER2 and Ki-67 indexes of breast primary lesions were obtained 10) Women in the reproductive period should use contraception for at least one month before screening, and commit to use contraception throughout the study period and continue to the specified time after the study
Exclusion criteria
Exclusion criteria: Exclusion criteria 1) Number of axillary lymph node dissection<10 2) Pathologically confirmed ipsilateral supraclavicular lymph node positive patients 3) Patients with ipsilateral internal mammary lymph node metastasis confirmed by pathology or imaging 4) Pregnant or lactating women 5) Receive stage I or II Breast reconstruction 6) There are serious non neoplastic medical complications that affect the implementation of radiotherapy 7) Malignant tumor history in the past 5 years (excluding previous lobular Carcinoma in situ, skin Basal-cell carcinoma, skin carcinoma in situ and cervical Carcinoma in situ) 8) Simultaneous contralateral breast cancer 9) Previous history of neck, chest, or ipsilateral axillary radiotherapy 10) Active collagen vascular disease 11) Remote site metastasis confirmed by pathology or imaging 12) Patients with primary mass staging of T4 13) Radiotherapy cannot be started within 12 weeks (or 8 weeks from the end of adjuvant chemotherapy) after breast cancer radical surgery (breast preservation surgery or mastectomy) 14) Other reviewers believe from the registration study that there are sufficient reasons for disqualification, such as potential discrepancies with the clinical protocol; Unable or unwilling to sign an informed consent form; Patients with mental illness or those who are unable to cooperate in treatment issued by medical institutions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local recurrence rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| 5-year distant metastasis rate;5-year survival rate without invasive tumor recurrence; | — |
Countries
CHINA
Contacts
Public ContactYaoxiong Xia
Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University)
Outcome results
None listed